AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Location
1800 El Camino Real, Suite D, Menlo Park, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -58.8%
Debt-to-equity 11.3 % +6.01%
Return On Equity -47.8 % +17%
Return On Assets -43 % +17.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.4M shares -8.29%
Common Stock, Shares, Outstanding 27.4M shares -8.36%
Entity Public Float 41.1M USD -62.2%
Weighted Average Number of Shares Outstanding, Basic 30.3M shares +1.46%
Weighted Average Number of Shares Outstanding, Diluted 30.3M shares +1.46%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 23.3M USD -53.4%
General and Administrative Expense 14.1M USD -4.33%
Operating Income (Loss) -37.4M USD +44.2%
Net Income (Loss) Attributable to Parent -34M USD +44%
Earnings Per Share, Basic -1 USD/shares +42.9%
Earnings Per Share, Diluted -1 USD/shares +42.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18M USD -46.3%
Cash, Cash Equivalents, and Short-term Investments 95.3M USD -16%
Assets, Current 64M USD -34.5%
Other Assets, Noncurrent 0 USD
Assets 67.2M USD -31.2%
Accounts Payable, Current 2.23M USD +30.1%
Employee-related Liabilities, Current 1.74M USD -17.3%
Accrued Liabilities, Current 2.71M USD -45%
Liabilities, Current 10M USD -32.5%
Liabilities 6.86M USD -31.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 64K USD -42.9%
Retained Earnings (Accumulated Deficit) -232M USD -17.1%
Stockholders' Equity Attributable to Parent 60.4M USD -31.1%
Liabilities and Equity 67.2M USD -31.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.6%
Net Cash Provided by (Used in) Financing Activities 65M USD +18525%
Net Cash Provided by (Used in) Investing Activities 9.19M USD -65%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.4M shares -8.36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.37M USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18M USD -46.3%
Deferred Tax Assets, Valuation Allowance 58.1M USD +39%
Deferred Tax Assets, Gross 58.1M USD +39%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34M USD +43.7%
Operating Lease, Liability, Current 13K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 28.7M USD +38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.08M USD +42.6%
Additional Paid in Capital 293M USD +2.36%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 6.63M USD -25.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%